UTHR:NSD-United Therapeutics Corporation (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 305.35

Change

0.00 (0.00)%

Market Cap

USD 13.60B

Volume

0.52M

Analyst Target

USD 144.78
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company involved in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. United Therapeutics Corporation was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-17 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
NBIX Neurocrine Biosciences Inc

N/A

USD 11.63B
VTRS Viatris Inc

N/A

USD 9.00B
LNTH Lantheus Holdings Inc

N/A

USD 7.11B
ALKS Alkermes Plc

N/A

USD 4.74B
ALVO Alvotech

N/A

USD 2.92B
HCM HUTCHMED DRC

N/A

USD 2.57B
BCRX BioCryst Pharmaceuticals Inc

N/A

USD 2.09B
SUPN Supernus Pharmaceuticals Inc

N/A

USD 1.80B
ANIP ANI Pharmaceuticals Inc

N/A

USD 1.51B
INDV Indivior PLC Ordinary Shares

N/A

USD 1.44B

ETFs Containing UTHR

MUUSAS:SW UBS (Irl) Fund Solutions .. 195.50 % 0.00 %

N/A

USD 0.46B
SANE 4.17 % 0.00 %

N/A

N/A
BIOT:SW L&G Pharma Breakthrough U.. 3.36 % 0.00 %

N/A

N/A
CURE:AU ETFS S&P Biotech ETF 2.48 % 0.00 %

N/A

USD 0.04B
SRHQ Elevation Series Trust - .. 2.36 % 0.00 %

N/A

N/A
FXH First Trust Health Care A.. 2.22 % 0.63 %

N/A

USD 0.90B
DSMC ETF Series Solutions 1.77 % 0.00 %

N/A

N/A
THNZ:XETRA 0.85 % 0.00 %

N/A

N/A
IQSM Iq Candriam ESG U.S. Mid .. 0.82 % 0.00 %

N/A

N/A
JMEE JPMorgan Market Expansion.. 0.62 % 0.00 %

N/A

USD 1.55B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

N/A

N/A
GURU Global X Guru Index ETF 0.00 % 0.75 %

N/A

N/A
LABD Direxion Daily S&P Biotec.. 0.00 % 1.00 %

N/A

USD 0.05B
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

N/A

USD 0.53B
PJP Invesco Dynamic Pharmaceu.. 0.00 % 0.56 %

N/A

N/A
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

N/A

N/A
BIOT:LSE L&G PHARMA BREAKTHROUGH G.. 0.00 % 0.00 %

N/A

N/A
XBI SPDR® S&P Biotech ETF 0.00 % 0.35 %

N/A

N/A
IS3T:F iShares IV Public Limited.. 0.00 % 0.00 %

N/A

N/A
QDVC:F iShares IV Public Limited.. 0.00 % 0.00 %

N/A

N/A
AFMC First Trust Active Factor.. 0.00 % 0.00 %

N/A

USD 0.06B
BIOT 0.00 % 0.00 %

N/A

N/A
FHH-F:CA First Trust AlphaDEX U.S... 0.00 % 0.00 %

N/A

CAD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -13.46% 51% F 36% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -13.46% 51% F 36% F
Trailing 12 Months  
Capital Gain 11.34% 72% C 72% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 11.34% 72% C 70% C-
Trailing 5 Years  
Capital Gain 156.04% 94% A 86% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 156.04% 94% A 84% B
Average Annual (5 Year Horizon)  
Capital Gain 24.73% 65% D 81% B-
Dividend Return 24.73% 65% D 80% B-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 28.60% 84% B 62% D
Risk Adjusted Return 86.47% 99% N/A 94% A
Market Capitalization 13.60B 100% F 94% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.